<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04108325</url>
  </required_header>
  <id_info>
    <org_study_id>YY-20394-004</org_study_id>
    <nct_id>NCT04108325</nct_id>
  </id_info>
  <brief_title>A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma</brief_title>
  <official_title>A Single-Arm, Open-Label, Multi-Center, Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai YingLi Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai YingLi Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an&#xD;
      oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory&#xD;
      peripheral T cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Objective Response Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DCR</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Disease control rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>up to 12 months</time_frame>
    <description>safety and tolerability of investigational product assessed as the number of participants experiencing adverse events (AEs, CTCAE5.0) or abnormalities in vital signs, laboratory tests, or electrocardiograms.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Relapsed or Refractory Peripheral T-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>YY-20394</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YY-20394</intervention_name>
    <description>Each treatment cycle is comprised of 28-day consecutive of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if there are benefit from the treatment and the toxicity is tolerable.</description>
    <arm_group_label>YY-20394</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and/or females over age 18&#xD;
&#xD;
          2. Histologically or cytologically confirmed diagnosis of relapsed or refractory&#xD;
             peripheral T cell lymphoma.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group performance status of 0 to 2.&#xD;
&#xD;
          4. Life expectancy of at least 3 months.&#xD;
&#xD;
          5. At least one measurable lesion according to IRWG.&#xD;
&#xD;
          6. Adequate organ function.&#xD;
&#xD;
          7. Had anti-tumor treatments greater than or equal to 2 weeks prior to the first dose of&#xD;
             investigational product (including TKI, chemotherapy, radiotherapy, immunotherapy and&#xD;
             major surgery).&#xD;
&#xD;
          8. Men and women of childbearing potential are willing to employ an effective method of&#xD;
             contraception for the entire duration of study and 6 months after the last dose.&#xD;
&#xD;
          9. Volunteers did not participate in other clinical trials within 1 month prior to study&#xD;
             entry.&#xD;
&#xD;
         10. Able to comply with the protocol judged by investigator.&#xD;
&#xD;
         11. Provision of signed and dated, written informed consent prior to any study- specific&#xD;
             evaluation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Previous treatment with any PI3K-delta ihinibitors. 2. Uncontrolled pleural effusion and&#xD;
        ascites. 3. the dosage of steroid hormone ( prednisone equivalent ) was greater than&#xD;
        20mg/day, and lasted for more than 14 days. 4. Medical conditions in swallowing,&#xD;
        malabsorption, or other chronic gastrointestinal disease that may hamper compliance and/or&#xD;
        absorption of the investigational agent. 5. During the study period, drugs that may prolong&#xD;
        the QT (such as anti arrhythmic drugs) could not be interrupted. 6. Evidence of central&#xD;
        nervous system involvement of the malignancy, including invasion of brain parenchyma and&#xD;
        meninges, or spinal cord compression. 7. Active, uncontrolled bacterial, viral, or fungal&#xD;
        infections, requiring systemic therapy(such as pneumonia). 8. Active infection with&#xD;
        hepatitis B and C virus ( Volunteers with HBsAg or HBcAb positive and HBV-DNA greater than&#xD;
        or equal to 1000 coRpies/ml or 200IU/ml; HCV antibody and HCV-RNA positive ). 9. History of&#xD;
        immune deficiency ( acquired or congenital ), or history of organ transplantation, or&#xD;
        allogeneic bone marrow or hematopoietic stem cell transplantation. 10. Presence of severe&#xD;
        or uncontrolled cardiovascular disease. 11. The baseline pregnancy test was positive in&#xD;
        pregnant women, lactating women or fertile women. 12. According to the judgement of the&#xD;
        investigator, there are concomitant diseases that seriously endanger the safety of patients&#xD;
        or affect the completion of the study (such as severe hypertension, diabetes, thyroid&#xD;
        diseases, etc.). 13. Medical history of other primary malignant tumors in the past 5 years&#xD;
        except for the following: clinically cured cervical in situ, local basal cell carcinoma of&#xD;
        the skin.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hanying Bao, PhD</last_name>
    <phone>86 21-5137069</phone>
    <email>hybao@yl-pharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yang Shu, MMeD</last_name>
    <phone>86 21-58320003</phone>
    <email>yshu@yl-pharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hematology Hospital of Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>3000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lugui Qiu, MD,PhD</last_name>
      <phone>022-23909083</phone>
      <email>qiulg@ihcams.ac.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

